Taiwan-based Formosa Pharmaceuticals announced that the company has entered into an exclusive licensing agreement with Tabuk Pharmaceuticals Manufacturing Company, for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05%, a patented innovative medicine for the treatment of inflammation and pain following ocular surgery in key regions of the Middle East and North Africa.
